Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 12/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512383 | 0.79 | DRD2 (0.38) | DRD2SIGMAR1DRD3HTR2AHTR2C | |
| SCHEMBL6512381 | 0.73 | DRD2 (0.52) | DRD2SIGMAR1DRD3 | |
| SCHEMBL384210 | 0.73 | DRD2 (0.52) | DRD2SIGMAR1DRD3 | |
| SCHEMBL681521 | 0.73 | — | — | |
| SCHEMBL1046369 | 0.73 | DRD2 (0.52) | DRD2SIGMAR1DRD3 | |
| SCHEMBL19546253 | 0.73 | DRD2 (0.52) | DRD2SIGMAR1DRD3 | |
| SCHEMBL6659994 | 0.70 | DRD2 (0.50) | DRD2SIGMAR1DRD3 | |
| Ammonia Solution, Strong SCHEMBL9858529 | 0.70 | — | — | |
| SCHEMBL2004909 | 0.68 | — | — | |
| Bromide SCHEMBL6660052 | 0.68 | DRD2 (0.48) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | claimed |
| EP-2352733-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | claimed |
| WO-2010060532-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | claimed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2352733-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010060532-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | ENPP2, TPX2, TPD52L2 | DRD2 173/4885SIGMAR1 1895/4885DRD3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.